|
|
|
51-200 employees
View all
|
|
biotechnology
|
|
255 State Street, 9th Floor,Boston,Massachusetts,US
|
|
Pieris Pharmaceuticals (NASDAQ: PIRS) is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. Pieris is currently hiring in Boston and Freising, Germany. See here for our full list of job openings and information on applying: https://www.pieris.com/careers
|
Pieris Pharmaceuticals Email Formats | Example Email Formats | Percentage |
---|---|---|
{last} | [email protected] |
75%
|
The widely used Pieris Pharmaceuticals email format is {last} (e.g. [email protected]) with 75% adoption across the company.
To contact Pieris Pharmaceuticals customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.